Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide

Table 1

Baseline patient and disease characteristics.

Characteristic	All patients; ()	L-SII; ()	H-SII; ()	value
Median age, (range)	57 (26-80)	59 (34-80)	58 (26-79)	0.83
Age group, (%)
<50 years	49 (29.3)	23 (28.7)	26 (29.9)	0.79
≥50 years	118 (70.7)	57 (71.3)	61 (70.1)
Gender, (%)
Female	57 (34.1)	27 (33.7)	30 (34.5)	0.81
Male	110 (65.9)	53 (66.3)	57 (65.5)
KPS, (%)
90-100	93 (55.7)	45 (56.3)	48 (55.1)	0.92
70-80	74 (44.3)	35 (43.7)	39 (44.9)
RTOG-RPA class, (%)
III	65 (38.9)	30 (37.5)	35 (40.2)	0.67
IV	72 (43.1)	34 (42.5)	38 (43.7)
V	30 (18.0)	16 (20.0)	14 (16.1)
Symptom duration, (%)
<3 months	121 (72.5)	55 (68.8)	66 (75.8)	0.52
≥3 months	46 (27.5)	25 (31.2)	21 (24.1)
Tumor location, (%)
Frontal	36 (21.6)	17 (21.3)	19 (21.9)	0.79
Parietal	30 (18.1)	14 (17.5)	16 (18.4)
Temporal	34 (20.5)	16 (20.0)	18 (20.7)
Occipital	17 (10.3)	10 (12.5)	7 (8.0)
Midline	18 (10.2)	8 (10.0)	10 (11.5)
Multilobar	32 (19.3)	15 (18.7)	17 (19.5)
Extent of surgery, (%)
GTR	60 (35.9)	27 (33.7)	33 (40.2)	0.34
STR	76 (45.5)	37 (46.3)	39 (44.9)
Biopsy	31 (18.6)	16 (20.0)	15 (14.9)
Pre-RT T2-FLAIR volume
<27.4 cc	82 (49.1)	38 (47.5)	44 (50.6)	0.73
≥27.4 cc	85 (50.9)	42 (52.5)	43 (49.4)
Corticosteroid use, (%)
Yes	112 (67.1)	46 (57.5)	66 (75.9)	0.09
No	55 (22.9)	34 (42.5)	21 (24.1)
Anticonvulsant use, (%)
Yes	57 (34.1)	31 (38.8)	26 (29.9)	0.28
No	110 (65.9)	49 (61.2)	61 (70.1)

L-SII: low systemic immune-inflammation index; H-SII: high-SII; KPS: Karnofsky performance score; RTOG-RPA: Radiation Therapy Oncology Group recursive partitioning analysis; GTR: gross total resection; STR: subtotal resection; RT: radiotherapy; FLAIR: fluid attenuation inversion recovery.